Significance of the potential role of pharmacological MRI (phMRI) in diagnosis of Parkinson’s disease

doi:10.1007/s11515-012-1023-7

Front Biol

2012, Vol. 7

Issue (4) : 307-312 https://doi.org/10.1007/s11515-012-1023-7

REVIEW

Significance of the potential role of pharmacological MRI (phMRI) in diagnosis of Parkinson’s disease

Feng YUE¹, Piu CHAN¹, Zhiming ZHANG²(

)

1. Department of Neurobiology and Neurology, Beijing Institute of Geriatrics, Xuanwu Hospital of Capital University of Medical Sciences, Beijing 100053, China; 2. Department of Anatomy and Neurobiology, University of Kentucky College of Medicine, Lexington, KY 40536, USA

Download: PDF(195 KB) HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

The initial diagnosis of Parkinson’s disease (PD) is currently based on a clinical assessment. Many patients who receive an initial diagnosis of PD have parkinsonian features related to other diseases such as essential tremor, vascular parkinsonism and atypical parkinsonian disorder. It has been challenging to differentiate PD from those disorders, especially in the early disease stages, due to an overlap of clinical signs and symptoms. Therefore, there is a great need for development of noninvasive, highly sensitive, and widely available imaging methods that can potentially be used to assistant physicians to make more accurate diagnosis of the disease; and to longitudinally monitor treatment of PD. Recent advance of pharmacological MRI (phMRI) technology allows non-invasively mapping functional stages for nigrostriatal dopamine (DA) system. This article aims to review research findings primarily from our group in nonhuman primates modeling the neurodegenerative disease on the value of phMRI techniques in the diagnosis of PD.

Keywords pharmacological MRI (phMRI) Parkinson’s disease phMRI techniques

Corresponding Author(s): ZHANG Zhiming,Email:zzhan01@uky.edu

Issue Date: 01 August 2012

Cite this article:

Feng YUE,Piu CHAN,Zhiming ZHANG. Significance of the potential role of pharmacological MRI (phMRI) in diagnosis of Parkinson’s disease[J]. Front Biol, 2012, 7(4): 307-312.

URL:

https://academic.hep.com.cn/fib/EN/10.1007/s11515-012-1023-7
https://academic.hep.com.cn/fib/EN/Y2012/V7/I4/307

Fig.1 phMRI reveals nigrostriatal system responsiveness to dopamine stimulation. Coronal MRI scans depicting areas of activation and deactivation (represented by the psedudocolor) in the brain after an APO or amphetamine challenge in unitalteral MPTP-lesioned nonhuman primates ().

Fig.2 phMRI responses in the nigrostriatal system. Depending on the means of stimulation, phMRI reveals a differential activations and deactivations in the nigrostriatal system. After APO stimulation (A-D) or d-amphetamine stimulation (E-H). **: <0.01; *: <0.05; unpaired -test ().

Fig.3 Lower TH fiber density in the ipsilesional putamen corresponds with higher phMRI activation. TH fiber density in the right putamen (R-Put) is inversely correlated with phMRI activation in the right motor cortex (R-MC) (A) and the right caudate nucleus (R-CD) (B).

Fig.4 Hemiparkinsonian nonhuman primates have markedly diminished dopaminergic function. K (100 mM)- and amphetamine (250 μM)-evoked DA release was significantly attenuated in the ipsilesional (A) putamen (Put) and (B) SNc; ***:<0.0001 (paired -test).

Fig.5 DA levels in the right SNc correlate with the BOLD responses in the right motor cortex. In animals with lower DA levels in the right SNc, less activation was observed in the right motor cortex

1	Andersen A H, Zhang Z, Barber T, Rayens W S, Zhang J, Grondin R, Hardy P, Gerhardt G A, Gash D M (2002). Functional MRI studies in awake rhesus monkeys: methodological and analytical strategies. J Neurosci Methods , 118(2): 141-152 doi: 10.1016/S0165-0270(02)00123-1 pmid:12204305
2	Arthurs O J, Boniface S (2002). How well do we understand the neural origins of the fMRI BOLD signal? Trends Neurosci , 25(1):27-31
3	Braak H, Del Tredici K (2008). Cortico-basal ganglia-cortical circuitry in Parkinson’s disease reconsidered. Exp Neurol , 212(1): 226-229 doi: 10.1016/j.expneurol.2008.04.001 pmid:18501351
4	Chen Q, Andersen A H, Zhang Z, Ovadia A, Gash D M, Avison M J (1996). Mapping drug-induced changes in cerebral R2* by Multiple Gradient Recalled Echo functional MRI. Magn Reson Imaging , 14(5): 469-476 doi: 10.1016/0730-725X(95)02100-8 pmid:8843359
5	Chin C L, Tovcimak A E, Hradil V P, Seifert T R, Hollingsworth P R, Chandran P, Zhu C Z, Gauvin D, Pai M, Wetter J, Hsieh G C, Honore P, Frost J M, Dart M J, Meyer M D, Yao B B, Cox B F, Fox G B (2008). Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI. Br J Pharmacol , 153(2): 367-379 doi: 10.1038/sj.bjp.0707506 pmid:17965748
6	Ding F, Luan L, Ai Y, Walton A, Gerhardt G A, Gash D M, Grondin R, Zhang Z (2008). Development of a stable, early stage unilateral model of Parkinson’s disease in middle-aged rhesus monkeys. Exp Neurol , 212(2): 431-439 doi: 10.1016/j.expneurol.2008.04.027 pmid:18547564
7	Fearnley J M, Lees A J (1991). Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain , 114(5): 2283-2301 doi: 10.1093/brain/114.5.2283 pmid:1933245
8	Honey G, Bullmore E (2004). Human pharmacological MRI. Trends Pharmacol Sci , 25(7): 366-374 doi: 10.1016/j.tips.2004.05.009 pmid:15219979
9	Jenkins B G, Sanchez-Pernaute R, Brownell A L, Chen Y C, Isacson O (2004). Mapping dopamine function in primates using pharmacologic magnetic resonance imaging. J Neurosci , 24(43): 9553-9560 doi: 10.1523/JNEUROSCI.1558-04.2004 pmid:15509742
10	Langston J W, Ballard P A Jr (1983). Parkinson’s disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N Engl J Med , 309(5): 310-321 doi: 10.1056/NEJM198308043090511 pmid:6602944
11	Nguyen T V, Brownell A L, Iris Chen Y C, Livni E, Coyle J T, Rosen B R, Cavagna F, Jenkins B G (2000). Detection of the effects of dopamine receptor supersensitivity using pharmacological MRI and correlations with PET. Synapse , 36(1): 57-65 doi: 10.1002/(SICI)1098-2396(200004)36:1<57::AID-SYN6>3.0.CO;2-K pmid:10700026
12	Nicklas W J, Youngster S K, Kindt M V, Heikkila R E (1987). MPTP, MPP⁺ and mitochondrial function. Life Sci , 40(8): 721-729 doi: 10.1016/0024-3205(87)90299-2 pmid:3100899
13	Pavese N, Brooks D J (2009). Imaging neurodegeneration in Parkinson’s disease. Biochim Biophys Acta , 1792(7): 722-729 pmid:18992326
14	Rasmussen I Jr (2010). Psychopharmacological MRI. Acta Neuropsychiatr , 22(1): 38-39 doi: 10.1111/j.1601-5215.2009.00432.x
15	Richardson J R, Caudle W M, Guillot T S, Watson J L, Nakamaru-Ogiso E, Seo B B, Sherer T B, Greenamyre J T, Yagi T, Matsuno-Yagi A, Miller G W (2007). Obligatory role for complex I inhibition in the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicol Sci , 95(1): 196-204 doi: 10.1093/toxsci/kfl133 pmid:17038483
16	Thiel C M (2009). Neuropharmacological fMRI. Neuropharmakologisches fMRT , 40: 233-238
17	Tracey I (2001). Prospects for human pharmacological functional magnetic resonance imaging (phMRI). J Clin Pharmacol , Suppl: 21S-28S pmid:11452725
18	Wu Y, Le W, Jankovic J (2011). Preclinical biomarkers of Parkinson disease. Arch Neurol , 68(1): 22-30 doi: 10.1001/archneurol.2010.321 pmid:21220674
19	Zhang Z, Andersen A, Grondin R, Barber T, Avison R, Gerhardt G, Gash D (2001). Pharmacological MRI mapping of age-associated changes in basal ganglia circuitry of awake rhesus monkeys. Neuroimage , 14(5): 1159-1167 doi: 10.1006/nimg.2001.0902 pmid:11697947
20	Zhang Z, Andersen A H, Ai Y, Loveland A, Hardy P A, Gerhardt G A, Gash D M (2006). Assessing nigrostriatal dysfunctions by pharmacological MRI in parkinsonian rhesus macaques. Neuroimage , 33, 636-643

[1]	Mohammad Jodeiri Farshbaf. Succinate dehydrogenase in Parkinson’s disease[J]. Front. Biol., 2017, 12(3): 175-182.
[2]	Jacqueline A. GLEAVE,Peter D. PERRI,Joanne E. NASH. Mitochondrial dysfunction in Parkinson’s disease: a possible target for neuroprotection[J]. Front. Biol., 2014, 9(6): 489-503.
[3]	Yingjun LIU, Jiawei ZHOU. Oligodendrocytes in neurodegenerative diseases[J]. Front Biol, 2013, 8(2): 127-133.

Viewed

Full text

Abstract

Cited

Shared

Discussed